Literature DB >> 1358045

Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood. An immunohistochemical investigation.

E George1, G A Niehans, P E Swanson, J G Strickler, T P Singleton.   

Abstract

Amplification and overexpression of the c-erbB-2 oncogene have been associated with a poor prognosis in breast cancer. The present study evaluates c-erbB-2 protein over-production in sarcomas and in small round-cell tumors of childhood by applying an immunohistochemical technique to formalin-fixed, paraffin-embedded tissues. This technique had previously demonstrated high sensitivity for the detection of c-erbB-2 activation. One peripheral neuroepithelioma demonstrated equivocal immunoreactivity for c-erbB-2 protein. There was no evidence of c-erbB-2 protein overproduction in 11 angiosarcomas, 21 chondrosarcomas, 10 epithelioid sarcomas, 14 Ewing's sarcomas, 20 hepatoblastomas, nine leiomyosarcomas, 12 liposarcomas, 13 malignant fibrous histiocytomas, nine malignant lymphomas, 15 neuroblastomas/ganglioneuroblastomas, 16 neurofibrosarcomas, 10 osteosarcomas, seven peripheral neuroepitheliomas, 10 rhabdomyosarcomas, six synovial sarcomas, and 20 Wilm's tumors. We conclude that overproduction of the c-erbB-2 protein is rare or absent in these neoplasms and that its detection is therefore not likely to be of practical utility in their pathologic evaluation and prognostication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358045

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.

Authors:  Susanne V Allander; Peter B Illei; Yidong Chen; Cristina R Antonescu; Mike Bittner; Marc Ladanyi; Paul S Meltzer
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Martina Vetter; Peter Würl; Hans J Holzhausen; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

3.  Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

Authors:  Karl-Ludwig Schaefer; Kristin Brachwitz; Yvonne Braun; Raihanatou Diallo; Daniel H Wai; Susanne Zahn; Dominik T Schneider; Cornelius Kuhnen; Arabel Vollmann; Gero Brockhoff; Helmut E Gabbert; Christopher Poremba
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

4.  Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.

Authors:  Michael Merker; Verena Pfirrmann; Sarah Oelsner; Simone Fulda; Thomas Klingebiel; Winfried S Wels; Peter Bader; Eva Rettinger
Journal:  Oncotarget       Date:  2017-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.